摘要
目的 探究低剂量阿替普酶联合替罗非班治疗急性脑梗死的疗效和安全性.方法 选取我院2022年8月~2024年2月收治的60例急性脑梗死患者为研究对象,遵循随机对照原则分为观察组和对照组,各30例.对照组采用常规剂量阿替普酶(0.9 mg/kg)联合替罗非班治疗,观察组则采用低剂量阿替普酶(0.6 mg/kg)联合替罗非班治疗.对比两组的疗效、预后、神经功能、生活质量和不良反应发生率.结果 治疗后观察组临床总有效率高于对照组(P<0.05);治疗后观察组的美国国立卫生研究院卒中量表(NIHSS)评分、改良Rankin量表(mRS)评分均低于对照组(P<0.05);治疗后观察组脑卒中专门化生存质量量表(SS-QOL)评分高于对照组(P<0.05);观察组颅内出血、消化道出血、皮肤瘀斑、过敏、牙龈出血等不良反应发生率低于对照组(P<0.05).结论 低剂量阿替普酶联合替罗非班治疗急性脑梗死的疗效及安全性较高,可提升生活质量,改善神经功能和预后.
Abstract
Objective To explore the efficacy and safety of low-dose alteplase combined with tirofiban in the treatment of acute cerebral infarction.Methods A total of 60 patients with acute cerebral infarction admitted to our hospital from August 2022 to February 2024 were selected as the study objects,and were divided into observation group and control group according to the principle of randomized control,with 30 cases in each group.The control group was treated with conventional dose of alteplase(0.9 mg/kg)combined with tirofiban,and the observation group was treated with low-dose of alteplase(0.6 mg/kg)combined with tirofiban.The efficacy,prognosis,neurological function,quality of life and incidence of adverse reactions were compared between the two groups.Results After treatment,the total effective rate of observation group was higher than that of control group(P<0.05).After treatment,the scores of National Institutes of Health Stroke Scale(NIHSS)and Modified Rankin Scale(mRS)in the observation group were lower than those in the control group(P<0.05).After treatment,the score of stroke specialized Quality of Life Scale(SS-QOL)in the observation group was higher than that in the control group(P<0.05).The incidence of adverse reactions such as intracranial hemorrhage,gastrointestinal hemorrhage,skin ecchymosis,allergy and gingival hemorrhage in the observation group was lower than that in the control group(P<0.05).Conclusion The efficacy and safety of low-dose alteplase combined with tirofiban in the treatment of acute cerebral infarction are high,which can improve the quality of life,improve neurological function and prognosis.